Erenumab-aooe - Biologic Drug Details

Summary for erenumab-aooe

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for erenumab-aooe Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for erenumab-aooe Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077	10,259,877	2036-04-22	Company disclosures
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077	11,407,838		Company disclosures
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077	11,466,090		Company disclosures
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077	9,102,731	2029-12-18	Company disclosures
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077	9,862,771	2035-06-26	Company disclosures

3) Low Certainty: US Patents for erenumab-aooe Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source